# Ciprofloxacin

```text
DRUG INFORMATION

  ADULT
    - No adult dose in this label - read the full label before dosing.
      Source: Read and found silent: the US FDA label for ciprofloxacin (Ciprofloxacin),
      retrieved 2026-08-29

  CHILD
    - Although effective in clinical trials, Ciprofloxacin is not a drug of first choice
      in the pediatric population due to an increased incidence of adverse reactions
      compared to controls. Quinolones, including Ciprofloxacin, cause arthropathy in
      juvenile animals [see Warnings and Precautions ( 5.12 ) and Nonclinical Toxicology
      ( 13.2 )] .
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'pediatric use',
      retrieved 2026-08-29

  RENAL IMPAIRMENT
    - These alternative pathways of drug elimination appear to compensate for the
      reduced renal excretion in patients with renal impairment.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'dosage and
      administration', retrieved 2026-08-29
    - Dosage guidelines for use in patients with renal impairment are shown in Table 4 .
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for ciprofloxacin
      (Ciprofloxacin), section 'dosage and administration', retrieved 2026-08-29
    - In patients with severe infections and severe renal impairment, a unit dose of 750
      mg may be administered at the intervals noted above.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'dosage and
      administration', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Nonetheless, some modification of dosage is recommended, particularly for patients
      with severe renal dysfunction [see Dosage and Administration ( 2.3 ) and Clinical
      Pharmacology ( 12.3 )]. 8.7 Hepatic Impairment In preliminary studies in patients
      with stable chronic liver cirrhosis, no significant changes in ciprofloxacin
      pharmacokinetics have been observed.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'use in specific
      populations', retrieved 2026-08-29
    - The pharmacokinetics of ciprofloxacin in patients with acute hepatic
      insufficiency, have not been studied.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY   [ AVOID ]
    The label says not to use it. Read the quote below before deciding.
    - Pregnancy Category C There are no adequate and well-controlled studies in pregnant
      women.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'pregnancy',
      retrieved 2026-08-29
    - Ciprofloxacin should not be used during pregnancy unless the potential benefit
      justifies the potential risk to both fetus and mother.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'pregnancy',
      retrieved 2026-08-29
    - An expert review of published data on experiences with ciprofloxacin use during
      pregnancy by TERIS–the Teratogen Information System–concluded that therapeutic
      doses during pregnancy are unlikely to pose a substantial teratogenic risk
      (quantity and quality of data=fair), but the data are insufficient to state that
      there is no risk.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Ciprofloxacin is excreted in human milk.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'nursing mothers',
      retrieved 2026-08-29
    - The amount of ciprofloxacin absorbed by the nursing infant is unknown.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'nursing mothers',
      retrieved 2026-08-29
    - Because of the potential risk of serious adverse reactions (including articular
      damage) in infants nursing from mothers taking Ciprofloxacin, a decision should be
      made whether to discontinue nursing or to discontinue the drug, taking into
      account the importance of the drug to the mother.
      Source: US FDA label for ciprofloxacin (Ciprofloxacin), section 'nursing mothers',
      retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)